EGLN1 and cancer: Any cytoplasmic expression of PHD2 and PHD3 (weak, moderate, or strong) in cancer cells was observed in 100% of patients in the Helsinki training cohort and 100% and 91.1% of patients in the Turku validation cohort, respectively.